Can Fite Biopharma logo

Can Fite Biopharma Share Price Today

(NASDAQ: CANF)

Can Fite Biopharma share price is $1.62 & ₹140.89 as on 6 Mar 2025, 2.30 'hrs' IST

$1.62

Market is closed - opens 8 PM, 06 Mar 2025

View live Can Fite Biopharma share price in Dollar and Rupees. Guide to invest in Can Fite Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Can Fite Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Can Fite Biopharma share price movements

  • Today's Low: $1.58
    Today's High: $1.67

    Day's Volatility :5.66%

  • 52 Weeks Low: $1.29
    52 Weeks High: $4.69

    52 Weeks Volatility :72.49%

Can Fite Biopharma (CANF) Returns

PeriodCan Fite Biopharma LtdIndex (Russel 2000)
3 Months
5.88%
0.0%
6 Months
-30.41%
0.0%
1 Year
-23.94%
0.0%
3 Years
-85.41%
-11.6%

Can Fite Biopharma (CANF) Key Statistics

in dollars & INR

Previous Close
$1.62
Open
$1.63
Today's High
$1.6721
Today's Low
$1.5775
Market Capitalization
$10.2M
Today's Volume
$40.9K
52 Week High
$4.69
52 Week Low
$1.29
Revenue TTM
$667.0K
EBITDA
$-7.8M
Earnings Per Share (EPS)
$-2.6
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-157.62%

How to invest in Can Fite Biopharma Stock (CANF) from India?

It is very easy for Indian residents to invest directly in Can Fite Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Can Fite Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Can Fite Biopharma or CANF on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Can Fite Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Can Fite Biopharma shares which would translate to 0.537 fractional shares of Can Fite Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Can Fite Biopharma, in just a few clicks!

Returns in Can Fite Biopharma (CANF) for Indian investors in Rupees

The Can Fite Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Can Fite Biopharma investment value today

Current value as on today

₹81,005

Returns

₹18,995

(-18.99%)

Returns from Can Fite Biopharma Stock

₹23,944 (-23.94%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Can Fite Biopharma (CANF)

22%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Can Fite Biopharma Stock from India on INDmoney has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Can Fite Biopharma

Analyst Forecast on Can Fite Biopharma Stock (CANF)

What analysts predicted

Upside of 764.2%

Target:

$14.00

Current:

$1.62

Insights on Can Fite Biopharma Stock (Ticker Symbol: CANF)

  • Price Movement

    In the last 1 month, CANF stock has moved up by 14.1%
  • Decreasing Revenue

    Revenue is down for the last 9 quarters, 205.0K → 158.0K (in $), with an average decrease of 3.0% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -1.67M → -1.97M (in $), with an average decrease of 5.9% per quarter
  • CANF vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 90.4%
  • CANF vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 137.1%

Can Fite Biopharma Technicals Summary

Sell

Neutral

Buy

Can Fite Biopharma is currently in a neutral trading position according to technical analysis indicators.

Can Fite Biopharma (CANF) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Can Fite Biopharma Ltd logo
16.55%
-30.41%
-23.94%
-85.41%
-88.79%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Can Fite Biopharma Ltd logo
NA
NA
0.0
0.0
-1.58
-0.57
NA
0.0
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Can Fite Biopharma Ltd logo
NA
$10.2M
-88.79%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Can Fite Biopharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Organization
Can Fite Biopharma
Employees
8
CEO
Mr. Motti Farbstein
Industry
Health Technology

Management People of Can Fite Biopharma

NameTitle
Dr. Pnina Fishman Ph.D.
Founder, Chief Scientific Officer & Executive Chairperson
Mr. Motti Farbstein
CEO and Chief Financial & Operating Officer
Dr. Sari Fishman Ph.D.
Vice President of Business Development
Dr. Ilan Cohn Ph.D.
Co-Founder & Director
Dr. Stephen A. Harrison FACP, M.D.
Member of Clinical Advisory Board & Consulting Chief Medical Officer

Important FAQs about investing in CANF Stock from India :

What is Can Fite Biopharma share price today?

Can Fite Biopharma share price today stands at $1.62, Open: $1.63 ; Previous Close: $1.62 ; High: $1.67 ; Low: $1.58 ; 52 Week High: $4.69 ; 52 Week Low: $1.29.

The stock opens at $1.63, after a previous close of $1.62. The stock reached a daily high of $1.67 and a low of $1.58, with a 52-week high of $4.69 and a 52-week low of $1.29.

Can Indians buy Can Fite Biopharma shares?

Yes, Indians can invest in the Can Fite Biopharma (CANF) from India.

With INDmoney, you can buy Can Fite Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Can Fite Biopharma at zero transaction cost.

How can I buy Can Fite Biopharma shares from India?

It is very easy to buy Can Fite Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Can Fite Biopharma (CANF) be purchased?

Yes, you can buy fractional shares of Can Fite Biopharma with INDmoney app.

What are the documents required to start investing in Can Fite Biopharma stocks?

To start investing in Can Fite Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Can Fite Biopharma Stock (CANF)?

Today’s highest price of Can Fite Biopharma (CANF) is $1.67.

Today’s lowest price of Can Fite Biopharma (CANF) is $1.58.

What is today's market capitalisation of Can Fite Biopharma?

Today's market capitalisation of Can Fite Biopharma CANF is 10.2M

What is the 52 Week High and Low Range of Can Fite Biopharma Stock (CANF)?

  • 52 Week High

    $4.69

  • 52 Week Low

    $1.29

What are the historical returns of Can Fite Biopharma (CANF)?

  • 1 Month Returns

    16.55%

  • 3 Months Returns

    -30.41%

  • 1 Year Returns

    -23.94%

  • 5 Years Returns

    -88.79%

Who is the Chief Executive Officer (CEO) of Can Fite Biopharma ?

Mr. Motti Farbstein is the current Chief Executive Officer (CEO) of Can Fite Biopharma.